PHGE Earnings Prediction
The chart below shows how PHGE performed 10 days before and after its earnings report, based on data from the past quarters. Typically, PHGE sees a +12.52% change in stock price 10 days leading up to the earnings, and a -11.87% change 10 days following the report. On the earnings day itself, the stock moves by -3.65%. This data can give you a slight idea of what to expect for the next quarter's release.
PHGE Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
--
--
--
Gross Margin
--
--
--
Operating Margin
--
--
--
Net Margin
--
--
--
EPS
0.59
553.85%
1375.00%
No Data Available
PHGE Earnings Analysis
BiomX Inc. Corporation (PHGE.A) Earnings Conference Call
Positive
Net Income Turnaround: Net income was $9.6 million for the third quarter of 2024, compared to a net loss of $7.9 million for the same period in 2023, reflecting a significant turnaround in financial performance.
R&D Expense Increase: Research and development expenses increased to $7.3 million for the third quarter of 2024, compared to $5.6 million for the same period in 2023, indicating a strong commitment to advancing product development.
Clinical Trial Progress: The company completed patient enrollment for the BX211 Phase 2 trial of DFO, with top-line results expected in the first quarter of 2025, showcasing progress in clinical trials.
Liquidity Position Analysis: Cash, cash equivalents, and short-term deposits as of September 30, 2024, were $24.7 million, demonstrating a solid liquidity position compared to $30.7 million as of December 31, 2023, with sufficient funds to support operations into the fourth quarter of 2025.
Reverse Stock Split Implementation: The company successfully implemented a 1-for-10 reverse stock split in August 2024, consolidating outstanding shares without affecting the par value of the common stock.
Negative
Cash Balance Decline: Cash balance, short-term deposits and restricted cash as of September 30, 2024, were $24.7 million, compared to $30.7 million as of December 31, 2023.
Cash Flow Decline: The decrease was primarily due to net cash used in operating activities and the repayment of our Hercules debt facility.
R&D Expense Increase: Research and development expenses, net were $7.3 million for the third quarter of 2024, compared to $5.6 million for the same period in 2023.
Administrative Expense Increase: General and administrative expenses were $3.2 million for the third quarter of 2024, compared to $2.2 million for the same period in 2023.
Operating Cash Flow Decline: Net cash used in operating activities for the nine months ended September 30, 2024, was $30.7 million, compared to $15 million for the same period in 2023.
PHGE FAQs
How does PHGE typically perform around its earnings report dates?
Is BiomX Inc. (PHGE) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
PHGE Earning Call Sentiment
BiomX Inc. (PHGE) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
PHGE.A
3.05%Positive
The earnings call presents a mixed picture. On the positive side, the company has secured additional funding and reported a net income, reversing a previous loss. However, concerns include manufacturing delays, a decrease in cash balance, and goodwill impairment. The reverse stock split and competitive pressures add uncertainty. The Q&A suggests the manufacturing delay may be a one-off, but the lack of clear management responses raises caution. Overall, the positive and negative factors balance out, leading to a neutral sentiment.